RADIATION THERAPY TECHNIQUES AND COMBINATION TREATMENTS FOR SARCOMA
Professor Angela Hong, Director and
co-Chair of Scientific Advisory Committee,
Australia and New Zealand Sarcoma Association (ANZSA)
RESEARCHER PROFILE
Filmed Sydney, Australia | January 2025
Professor Angela Hong MBBS, MMed, PhD, FRANZCR is a Professor at Sydney Medical School of the University of Sydney. She is a radiation oncologist and has been a member of the Multidisciplinary Bone and Soft Tissue Tumour Clinic at Royal Prince Alfred Hospital/Chris O’Brien Lifehouse for the past 15 years.
She is also the Director and co-chair of the Scientific Advisory Committee for the Australia and New Zealand Sarcoma Association (ANZSA), a non-profit organisation aimed at enhancing treatment outcomes for sarcoma patients across Australia and New Zealand.
As a radiation oncologist located in Sydney, Australia, Professor Hong is focused on treating patients with bone and soft tissue sarcoma. And as a clinician scientist, her research focuses on developing innovative radiation therapy technique and combination treatments to improve the outcome for patients with sarcoma.
After earning her medical degree from the University of Sydney, Angela undertook an 18-month fellowship in the United States to gain additional experience before returning to Sydney to start her formal training in radiation oncology. She later completed her PhD, concentrating on radiosensitivity in skin cancer sarcoma.
Professor Hong believes in a multidisciplinary approach to managing sarcoma, given its rarity and the complexities involved in diagnosis and treatment. She is actively involved in clinical research and recently contributed to an international trial led by Sarcoma Alliance for Research through Collaboration (SARC) in the United States and the Australia and New Zealand Sarcoma Association (ANZSA) in Australia. The trial examined the advantages of including immunotherapy in the treatment regimen for high-risk soft tissue sarcoma, resulting in a notable improvement in two-year disease-free survival rates.
-
DNA repair on the Fanconi anaemia pathway
Associate Professor Wayne Crismani is an internationally recognised expert in DNA repair, with a particular focus on Fanconi anaemia (FA)—a cancer-predisposition and bone marrow failure syndrome marked by extreme sensitivity to DNA damage. Based at St Vincent’s Institute in Melbourne, he leads a research program dedicated to understanding the genetic, cellular, and reproductive consequences of FA. He is currently supported by a Victorian Cancer Agency Mid-Career Fellowship and funding from the National Health and Medical Research Council.
-
Discovery of RANK Ligand’s role in bone metabolism and the immune system to treat osteoporosis
Emeritus Professor Jack Martin’s research began a discovery cascade that led to the identification of a new protein and the development of a novel and effective drug therapy that is now used worldwide to treat osteoporosis, cancer and other diseases.
-
Big data research in maternal, perinatal and renal health epidemiology
Dr Erandi Hewawasam is a Research Fellow at the National Perinatal Epidemiology and Statistics Unit within the Centre for Big Data Research in Health at University of New South Wales (UNSW). Her work focuses on maternal and reproductive health, chronic diseases (e.g., kidney disease, endometriosis), and early-life outcomes. She is the Program Manager for the Fertility Medicine Data Asset for Australia (FM-DATA), an MRFF-funded national infrastructure project linking fertility, hospital, Medicare, pharmaceutical, and perinatal datasets covering more than 40 million individuals. She also coordinates the Early Life Course Platform, integrating around 20 New South Wales and Australian federal administrative datasets to support population health research.
